Dolutegravir/rilpivirine - Janssen/Viiv Healthcare

Drug Profile

Dolutegravir/rilpivirine - Janssen/Viiv Healthcare

Alternative Names: Juluca; Rilpivirine/dolutegravir

Latest Information Update: 27 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Janssen Research & Development; ViiV Healthcare
  • Class 3-ring heterocyclic compounds; Amides; Antiretrovirals; Nitriles; Oxazines; Pyrimidines; Small molecules
  • Mechanism of Action HIV integrase inhibitors; Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered HIV infections

Most Recent Events

  • 23 Mar 2018 The Committee for Medicinal Products for Human Use recommends approval of dolutegravir/ripivirine for HIV infections in European Union
  • 23 Mar 2018 The final European Commission decision on European approval for dolutegravir/rilpivirine in HIV infections (Treatment-experienced) is expected towards the end of 2Q 2018
  • 08 Dec 2017 Dolutegravir/rilpivirine is not yet available for HIV infections (Maintenance therapy, Treatment-experienced) in USA (PO) (literature review)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top